GN-HEARING
3.5.2021 09:02:09 CEST | Business Wire | Press release
GN Hearing, the global leader in hearing aid innovation, today unveils Interton Move , the newest addition to its leading portfolio of hearing solutions that caters to all user needs. Interton Move makes great sound quality and best-in-class connectivity more accessible, helping hearing care professionals meet the diverse needs of people living with hearing loss.
The lineup of 10 essential hearing aids represents the biggest upgrade in the history of Interton. People from across the hearing loss spectrum can now get more out of life with greater choice than ever before. Most importantly, people can now feel confident when communicating with friends and family as they can focus on what they want to hear. They benefit from improved listening comfort in different environments, made possible thanks to a new, faster, more powerful sound processing platform. The launch also presents new rechargeability options and full smartphone support with direct audio streaming and an app for personalization. These vital elements result in high-quality, yet affordable hearing care with all the benefits of GN’s leading and proven technology.
Globally, 430 million people live with hearing loss and only 1 in 5 people who could benefit from hearing aids actually use them.1 Untreated hearing loss has wide-reaching impacts on a person’s quality of life and happiness. As hearing loss can be perceived by some as a small problem and something to ignore or put up with, hearing aids may be seen as an overwhelming solution. With the new Interton Move portfolio, hearing care professionals can now offer simple and straightforward hearing care to more people than ever before.
GN Hearing CEO and President, Gitte Aabo, explains: “At GN Hearing, we want to make life sound better for every person with hearing loss. Treating hearing loss can radically transform an individual’s life, as they can hear more and return to doing what they love. With the launch of Interton Move, we’re pleased to support the crucial role that hearing care professionals play in helping people access the hearing care they need.”
The extensive portfolio includes a mini rechargeable Receiver-in-Ear (RIE), a mini Behind-the-Ear (BTE), custom hearing aids, and even a ‘Super Power’ option for profound hearing loss. The rechargeable RIE model and its matching desktop charger provide freedom from batteries and up to 30 hours of use on a single charge.
All Interton Move users can enjoy high-quality streaming of calls, music, and other audio directly from compatible Apple and AndroidTM devices. Meanwhile, the Interton Sound smartphone app enables users to personalize their hearing experience and connect to GN’s extensive range of wireless accessories.
All aspects of the fitting and onboarding process have been upgraded to improve the user experience and to ensure that the start of a person’s hearing journey is as seamless as possible. To make consulting easier for hearing care professionals, the Interton Fitting Software follows the same workflow as all other GN Hearing solutions.
Interton Move will roll out globally and be available in the first countries from May 2021.
NOTES TO EDITORS
About Interton
Interton was founded in Germany in 1962 and is part of the GN Group. Interton hearing aids are designed in Denmark and powered by pioneering technology that has transformed the sound quality, functionality, and comfort of hearing aids.
Visit our homepage interton.com – and connect with us on Facebook.
About GN Group
The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com and connect with us on LinkedIn and Facebook .
© 2021 GN Hearing A/S. All rights reserved. Interton is a trademark of GN Hearing A/S. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.
1 WHO: Deafness and hearing loss: https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss . Accessed on April 12, 2021. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005229/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom